Provided by Tiger Fintech (Singapore) Pte. Ltd.

Edgewise Therapeutics, Inc.

16.35
+0.60003.81%
Volume:521.25K
Turnover:8.31M
Market Cap:1.72B
PE:-10.54
High:16.37
Open:15.52
Low:15.48
Close:15.75
52wk High:38.12
52wk Low:10.60
Shares:105.35M
Float Shares:60.53M
Volume Ratio:0.59
T/O Rate:0.86%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.5508
EPS(LYR):-1.4480
ROE:-27.41%
ROA:-19.06%
PB:2.92
PE(LYR):-11.29

Loading ...

Truist Lowers Price Target on Edgewise Therapeutics to $46 From $50, Keeps Buy Rating

MT Newswires Live
·
Jul 07

Edgewise Therapeutics Initiated at Buy by HC Wainwright & Co.

Dow Jones
·
Jun 30

Edgewise's Sevasemten Program Poised to Succeed in Becker Muscular Dystrophy, RBC Capital Says

MT Newswires Live
·
Jun 27

Wedbush Cuts Price Target on Edgewise Therapeutics to $35 From $40, Keeps Outperform Rating

MT Newswires Live
·
Jun 27

BUZZ-Edgewise Therapeutics falls after mid-stage study data found insufficient for accelerated approval

Reuters
·
Jun 27

BRIEF-Edgewise Therapeutics Reports Positive Results On Sevasemten Program

Reuters
·
Jun 26

Edgewise Therapeutics Inc. Advances Sevasemten Program with Positive FDA Feedback and Clear Path for Becker Therapy Approval

Reuters
·
Jun 26

Edgewise Therapeutics Price Target Maintained With a $48.00/Share by RBC Capital

Dow Jones
·
Jun 05

Edgewise Therapeutics to Present at Annual Goldman Sachs Global Healthcare Conference

Reuters
·
Jun 03

Treehouse Foods, GeneDx Holdings See Activist Action -- Barrons.com

Dow Jones
·
May 17

Edgewise Therapeutics Inc. to Present at RBC Capital Markets Global Healthcare Conference

Reuters
·
May 14

Wedbush Adjusts Price Target on Edgewise Therapeutics to $40 From $43, Maintains Outperform Rating

MT Newswires Live
·
May 09

Edgewise Therapeutics' Q1 Net Loss Widens; Shares Down Over 3%

MT Newswires Live
·
May 08

Edgewise Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 08

BRIEF-Edgewise Therapeutics Q1 Operating Expenses USD 45.959 Million

Reuters
·
May 08

Edgewise Therapeutics Inc. Chief Scientific Officer Russell Alan J Reports Disposal of Common Shares

Reuters
·
May 08

John R. Moore, General Counsel, Reports Disposal of Edgewise Therapeutics Inc. Common Shares

Reuters
·
May 08

Guggenheim Starts Edgewise Therapeutics With Buy Rating, $41 Price Target

MT Newswires Live
·
Apr 30

Edgewise Therapeutics Says Believes Atrial Fibrillation Not Driven by EDG-7500 in Phase 2 Trial, RBC Says

MT Newswires Live
·
Apr 04

Edgewise Therapeutics Cut to Sector Perform From Sector Outperform by Scotiabank

Dow Jones
·
Apr 03